THE European Medicines
Agency’s Committee for Medicinal
Products for Human Use (CHMP)
has recommended varying levels of
marketing authorisation for six new
products.
The approvals are for Gazyvaro
(obinutuzumab), Plegridy
(peginterferon beta-1a), Nuwiq
(simoctogog alfa), Simbrinza
(brinzolamide / brimonidine
tartrate) and Envarsus (tacrolimus).
Additionally, the CHMP
recommended extensions
of indications for Arzerra
(ofatumumab), Halaven (eribulin
mesylate) and Vfend (Voriconazole).
The CHMP also recommended a
conditional marketing authorisation
for Translarna (ataluren), an orphan
medicine for the treatment of
Duchenne muscular dystrophy
caused by nonsense mutations.
It is to be used for patients aged
five years or older who are able to
walk.The above article was sent to subscribers in Pharmacy Daily's issue from 27 May 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 May 14
THOUGH women make up 60% of pharmacy graduates and pharmacists, they hold only 34% of leadership and ownership roles, according to Andria Aird, a community pharmacist, pharmacy owner, and Board Director of Blooms The Chemist.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.